MU Department of Medicine 2011-2013 Annual Report Feb. 2014 | Page 16

16

Annual Report

University of Missouri- Columbia

Overview of Research

Editorial Boards • Funded Research • Publications

The Division of Cardiovascular Medicine has been highly

trials were begun, 10 trials were completed, and 5 previously

successful in the recent past in its pursuits of research and

initiated trials were continued. Revenue generated by these

scholarship. Our research efforts can be grouped into 3 broad

trials during this time period included $1,389,481 for the newly

categories: 1) basic mechanisms of cardiovascular disease, 2)

initiated trials; $1,283,398 for completed trials and $393,917

multicenter clinical trials of novel therapeutics, and 3) clinical

for ongoing trials. In addition, we became involved with the

and translational research.

Heart Failure Network through Washington University in St. Louis

In the basic research arena, William Fay, MD continued his
NIH-funded research program that focuses on the role of blood
clotting proteins in the development of obstructive disease in
coronary arteries and vein bypass grafts. In 2012 Dr. Fay received
notification of successful funding of a Merit Review Award
from the Department of Veterans Affairs and an NIH R44 award.
The VA grant will focus on the role of plasminogen activator
inhibitor-1 (PAI-1) in vein graft disease. Hongmin Sun, PhD,
whose work is also funded by the NIH, published an intriguing
series of papers, including one in the Proceedings of the National
Academy of Sciences, USA, dealing with the mechanisms
underlying the pathogenesis of bacterial infection. Dr. Sun’s work
addresses a major threat to patients with permanent pacemakers

with revenue generated for our participation including $21,415.
These monies provided salary support for research nurses and
provided faculty funds for a variety of academic pursuits. The
trials cover a broad range of therapeutic areas, including acute
coronary syndromes, atrial fibrillation, anticoagulation, implanted
cardiac devices, lipid management, chelation therapy, and heart
failure management. Two of the trials involved a novel factor Xa
inhibitor, apixaban, which recently received FDA